The National Health Insurance Scheme (NHIS) and Roche Products Nigeria Limited said it will work assiduously to accelerate the drive towards the attainment of Universal Healthealth Coverage (UHC) in the area of Cancer Care Reimbursement initiative.
The foremost health insurance agency and leading drug maker have signed a Memorandum of Understanding (MOU) at the NHIS headquarters in Abuja.
The partnership will enable both healthcare institutions to engage in capacity building initiatives that is designed to support the health insurance ecosystem.
The Executive Secretary and Chief Executive Officer of NHIS Prof Mohammed Sambo, stated that the Scheme puts an invaluable premium on strategic stakeholders’ in the execution of its mandate to bring affordable and quality healthcare to all Nigerians.
He added that the implementation of its ten-year strategic plan was on course.
The Executive Secretary who was represented by the General Manager, Legal Services, Bar. Blessing Nienge, disclosed that the ongoing reforms in the Scheme has as its central objective in making healthcare affordable.
He stated that the initiative is to ensure that drugs is made available, affordable and receiving favourable attention.
General Manager, Roche Products Ltd., Nigeria, Dr Ladi Hammeed described the partnership as a significant and commendable milestone for cancer care in Nigeria.
He expressed optimism that cancer patients will no longer have to deal with the catastrophic consequences of the diagnosis of the disease.
While noting that funding for early treatment, comprehensive care inclusive of surgery, radiotherapy, chemotherapy and targeted therapy will improve treatment outcomes and ultimately the survival of the diagnosed patients.
The MOU document outlines key areas of partnership between the two organizations along three main themes aimed at significantly improving patients’ access to innovative cancer medicines.
The arrangement allows both parties to partner on an innovative cost sharing mechanism, by way of sharing a proportion of the cost of the medicines. Expectedly, this will ensure affordability of the drugs for patients at the treatment centers.
NHIS is Nigeria’s foremost health insurance implementating agency while Roche is a leading biotech company, with differentiated and innovative medicines in various disease areas, including oncology, immunology, infectious diseases, ophthalmology and the central nervous system.
The partnership will be piloted in designated centers across the six geopolitical zones of the country.